Selecta and Genovis enter exclusive license agreement

By The Science Advisory Board staff writers

October 21, 2021 -- Selecta Biosciences and Genovis have inked a strategic licensing agreement to advance a next-generation immunoglobulin G (IgG) protease for use in gene therapy and certain autoimmune diseases.

The partnership leverages Genovis' proprietary IgG protease, IdeXork (Xork), and Selecta's ImmTOR platform to enable the dosing of transformative gene therapies in patients with preexisting adeno-associated virus immunity and to treat certain IgG-mediated autoimmune diseases.

Under the agreement, Selecta obtains exclusive worldwide rights to Xork.

New platform identifies best viral vectors for gene therapy
Researchers have developed a novel computational platform that identifies the best viral vector to deliver a gene therapy to its target. The technology,...
Waters, Genovis team up on automated CQA characterization
Waters and Genovis are working together to develop and market routine biopharmaceutical characterization workflows of critical quality attributes (CQAs)...
Selecta, AskBio start gene therapy ImmTor trial
Selecta Biosciences and Asklepios BioPharmaceutical (AskBio) have initiated a phase I clinical trial to evaluate the safety and preliminary efficacy of...
Selecta Biosciences validates tech that could improve gene therapies
Selecta Biosciences has achieved preclinical data validating its ImmTOR platform to enhance the efficacy, safety, and durability of adeno-associated viral...
Regulatory Roundup: Gene therapies, bispecific antibodies lead new approvals
Welcome to Regulatory Roundup, a new Science Advisory Board feature that tracks recent regulatory activities in the life sciences industry. Recent approvals...

Copyright © 2021

Cell Bio 2021
December 11-15
San Diego, California United States
Antibody Engineering and Therapeutics
December 13-17
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter